These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 31580492

  • 1. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
    Wang LX, Quach HT, Moodabigil NV, Davis EJ, Sosman JA, Dusetzina SB, Johnson DB.
    Cancer; 2020 Jan 15; 126(2):322-328. PubMed ID: 31580492
    [Abstract] [Full Text] [Related]

  • 2. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T.
    JAMA Dermatol; 2020 Sep 01; 156(9):982-986. PubMed ID: 32667663
    [Abstract] [Full Text] [Related]

  • 3. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
    Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN.
    Ann Oncol; 2018 Jan 01; 29(1):250-255. PubMed ID: 29045547
    [Abstract] [Full Text] [Related]

  • 4. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 01; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 5. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ, Weppler A, Bhave P, Allayous C, Patrinely JR, Ott P, Sandhu S, Haydon A, Lebbe C, Johnson DB, Long GV, Menzies AA, Carlino MS.
    J Immunother Cancer; 2021 May 01; 9(5):. PubMed ID: 33963010
    [Abstract] [Full Text] [Related]

  • 6. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
    Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P, Panageas KS, Wolchok JD, Chapman PB.
    JAMA Oncol; 2018 Jan 01; 4(1):98-101. PubMed ID: 28817755
    [Abstract] [Full Text] [Related]

  • 7. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV.
    Lancet Oncol; 2021 Jun 01; 22(6):836-847. PubMed ID: 33989557
    [Abstract] [Full Text] [Related]

  • 8. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
    Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.
    Ann Oncol; 2017 Feb 01; 28(2):368-376. PubMed ID: 27687304
    [Abstract] [Full Text] [Related]

  • 9. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS, Postow M, Lao CD, Schadendorf D.
    Oncologist; 2016 Oct 01; 21(10):1230-1240. PubMed ID: 27401894
    [Abstract] [Full Text] [Related]

  • 10. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN, Abushukair HM, Ababneh OE, Syaj SS, Al-Horani SS, Qarqash AA, Darabseh OA, Al-Sous MM, Al-Aomar SR, Ahmed YB, Haddad R, Al Qarqaz FA.
    Clin Transl Oncol; 2021 Sep 01; 23(9):1885-1904. PubMed ID: 33877531
    [Abstract] [Full Text] [Related]

  • 11. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
    Asher N, Marom EM, Ben-Betzalel G, Baruch EN, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G.
    Oncologist; 2019 May 01; 24(5):640-647. PubMed ID: 30777894
    [Abstract] [Full Text] [Related]

  • 12. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
    Patrinely JR, Baker LX, Davis EJ, Song H, Ye F, Johnson DB.
    Cancer; 2020 Aug 01; 126(15):3448-3455. PubMed ID: 32463489
    [Abstract] [Full Text] [Related]

  • 13. Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.
    Klee G, Kurzhals J, Hagelstein V, Zillikens D, Recke A, Langan EA, Terheyden P.
    Melanoma Res; 2021 Oct 01; 31(5):464-471. PubMed ID: 34284462
    [Abstract] [Full Text] [Related]

  • 14. A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial.
    Fujimura T, Yoshino K, Kato H, Fukushima S, Ishizuki S, Otsuka A, Matsushita S, Amagai R, Muto Y, Yamazaki E, Kambayashi Y, Yahata T, Miyata T, Fujisawa Y, Asano Y.
    Br J Dermatol; 2024 Oct 17; 191(5):691-697. PubMed ID: 38833158
    [Abstract] [Full Text] [Related]

  • 15. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
    Huffman BM, Kottschade LA, Kamath PS, Markovic SN.
    Am J Clin Oncol; 2018 Aug 17; 41(8):760-765. PubMed ID: 28749795
    [Abstract] [Full Text] [Related]

  • 16. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.
    Eur J Cancer; 2017 Apr 17; 75():47-55. PubMed ID: 28214657
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
    Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM.
    J Immunother Cancer; 2021 May 17; 9(5):. PubMed ID: 33963015
    [Abstract] [Full Text] [Related]

  • 19. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva IPD, Batten M, Scolyer RA, Long GV, Wilmott JS.
    Cancer Cell; 2019 Feb 11; 35(2):238-255.e6. PubMed ID: 30753825
    [Abstract] [Full Text] [Related]

  • 20. Nivolumab plus ipilimumab in advanced melanoma.
    Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M.
    N Engl J Med; 2013 Jul 11; 369(2):122-33. PubMed ID: 23724867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.